Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools

Navigation

You are here: Home / Members / Moo J Cho
Moo J  Cho

Moo J Cho

  • PhD
  • Molecular Therapeutics

  • Associate Professor
  • UNC-Chapel Hill
  • m_j_cho@unc.edu
  • 919-966-1345
  • 1308 Kerr Hall Chapel Hill, NC 27599-7360

Area of Interest

CYTOSOLIC DELIVERY OF NUCELIC ACIDS
This research focuses on possible means of endosome-to-cytosol transfer of antisense oligonucleotides and siRNA. The working hypothesis behind the approach is based on the acidity and reductive environment of endosomes.

SYSEMIC DELIVERY OF CpG OLIGONUCLEOTIDES
Cancer immunotherapy with CpG oligos requires a conventional systemic route of administration. Our approach exploits use of endogenous anti-Gal antibodies as galactosylated CpG oligos or pre-made monovalent immune complexes for IV or SC route of administration.

A THIRD GENERATION PACLITAXEL FORMULATION
Our target drug concentration is 10 to 25 mg/ml. Upon IV administration, the drug should demonstrate a prolonged circulatory half-life, days in mice. In tumor bearing mice, our target delivery is 15-25 % injected dose per 100-200 mm3 tumor. The approach is based on exploiting a naturally occurring endogenous carrier.